Optic and Otic Side Effects of Molecular Targeted Therapies

O’Leary, Colleen

doi:10.1016/j.soncn.2014.05.004

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further supporting this hypothesis, previous reviews of primarily clinical case reports have revealed consistent patterns of chemotherapy-associated ocular toxicities due to multiple agents. 15,16 If visual pathway degeneration is a valid marker of dysfunctional brain activity, then research programmes aimed at detecting and preventing CRNT may benefit from utilising ophthalmic biomarkers. Indeed, several ophthalmic measures have shown promise in tracking disease progression in neurodegenerative diseases.…”

Section: Chemotherapy-related Neurotoxicitymentioning

confidence: 99%

Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research

Anderson

Holstein

Kedar

2020

Neuro-Ophthalmology

View full text Add to dashboard Cite

Chemotherapy-related neurotoxicity (CRNT) is an emerging public health concern. Visual pathway degeneration may be a symptom of CRNT. We surveyed the current literature for evidence of visual pathway degeneration in cancer patients receiving chemotherapy. A systematic review was conducted in PubMed. Six published articles met our inclusion criteria. The studies showed reduced retinal thickness, primarily in the retinal nerve fibre layer, and impaired inner retinal function in patients receiving chemotherapy. In summary, the current literature suggests chemotherapy may induce visual pathway degeneration. Future research may benefit from improving study design, exploring mechanisms of chemotherapy-related visual pathway degeneration, and incorporating these findings into biomarker development.

show abstract

Section: Chemotherapy-related Neurotoxicitymentioning

confidence: 99%